Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Donna Ryan MD

Donna H. Ryan MD

Professor Emerita, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana

Donna Ryan is Professor Emerita at Pennington Biomedical in Baton Rouge, LA, USA where she had a 30-year career in clinical research in obesity.

She was an investigator on POUNDS Lost, Look AHEAD, DPP, DASH and many other studies investigating the health benefits of weight loss by various intervention strategies. She was PI of a series of studies for the US Department of Defence which targeted military nutrition. Her personal research targeted improving primary care management of obesity.

Currently, Dr. Ryan serves as Past President of the World Obesity Federation, Co-Chair of the SELECT Steering Committee and member of the Data Safety Monitoring Board for setmelanotide.

She has more than 300 publications and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.


Dr. Ryan reports the following for the past 24 months (as of Feb 3, 2023):

  • Advisor/consultant: Altimmune, Amgen, Calibrate, Carmot, Epitomee, Gila, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Wondr Health, Xeno Bioscience, YSOPIA, Zealand 
  • Speaker’s Bureau: Novo Nordisk
  • Stock Options: Epitomee, Calibrate, Roman, Scientific Intake, Xeno Bioscience
  • Research: SELECT Steering Committee (Novo Nordisk) and DSMB(2) (Rhythm)